Current news and events

New immune-related breast cancer subtypes described in Nature Communications

First author Xavier Tekpli and senior author Vessela Kristensen
First author Xavier Tekpli and senior author Vessela Kristensen

In a study published December 3rd in Nature Communications, Xavier Tekpli in Vessela Kristensen’s group and their colleagues from the EMIT study report an immune-related breast cancer subtype which identifies patients with poor prognosis and in need of new treatment strategies.

Scientists from the EMIT study, from left to right:
Bjørn Naume, Therese Sørlie, Hege Russnes, Hege
Oma Ohnstad, Elin Borgen and Gry Aarum Geitvik.

 

 

How B cell receptor ligation and T cell help drives chronic pathological B cell expansion

First author Peter Huszthy, second author Ramakrishna Gopalakrishnan and senior author Bjarne Bogen
First author Peter Huszthy, second author Ramakrishna Gopalakrishnan and senior author Bjarne Bogen

B cell receptor ligation induces display of V-region peptides on MHC class II molecules to T cells." published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) this week, first author Peter Huszthy and researchers from Bjarne Bogen's group at the Department of Immunology demonstrate the importance of B cell receptor (BCR) ligation by antigen for Idiotype-driven T cell-B cell collaboration. Idiotype-driven T cell-B cell collaboration, if made chronic, may lead to the development of systemic autoimmune disease and B cell lymphomas.

Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2019

Award winners at the ceremony
Award winners at the ceremony

In order to stimulate excellent research and draw attention to the hospital's research activity, Oslo University Hospital reward outstanding publications every half-year.

Six research groups were awarded for their excellent papers published during the first half-year of 2019 on November 22nd. Each group received NOK 50.000 for use in further research. The prize winners then gave short presentations of their important findings.

 

Young researcher award to Peter Wold Eide at “Onkologisk Forum”

Dr. Peter Wold Eide, post doc in the Lothe lab received the "Young researcher award" for his scientific accomplishments during the 2019 Onkologisk forum held in Tromsø November 21st-22nd .

The evaluation committee pointed out his competence in cell biology, bioinformatics and pharmacogenomics, and that his research assessing drug sensitivities in combination with genomics in patient derived preclinical models is important for further development of precision oncology. 

Ceremony Friday November 15th:Ragnar Mørk legacy prize 2019 to Karl-Johan Malmberg

Karl-Johan Malmberg with Kjetil Taskén
Karl-Johan Malmberg with Kjetil Taskén

Karl Johan Malmberg from the Department of Cancer Immunology at Institute for Cancer Research has received Dr. Ragnar Mørk's Prize 2019 for his excellent research on natural killer (NK) cells. Malmberg's research has improved our understanding of how NK cells are activated, which opens new possibilities for using NK cells in cancer immunotherapy. Malmberg is currently exploring this concept in ongoing clinical trials.

Vessela Kristensen appointed Head of Research at the Department of Medical Genetics.

Vessela N. Kristensen
Vessela N. Kristensen

Vessela Kristensen is appointed Head of Research at the Section for Research and Development at the Department of Medical Genetics. 
During her 23 years at the Institute for Cancer research (1996-2019), she has lead multiple projects and attracted external funding for more than 40 mill. NOK leading 9 PhD students as a main supervisor. In the last 13 years (20006 - 2019) she has been professor I at Institute for clinical medicine, Campus Ahus, where she supervised additional 6 PhD students and generated external funding for 21 million NOK. "Now it is time for something new" says Vessela Kristensen.

Bridging the gap to proteomics with new high-parameter instruments at the Flow Cytometry Core Facility

Flow Cytometry Core Facility Staff
Flow Cytometry Core Facility Staff

Highly multiplexed analysis of cell suspensions or tissue sections is now available at the Institute of Cancer Research. The Flow Cytometry Core facility has recently installed a 30-parameter fluorescence flow cytometer (FACSSymphony A5) and a 135-channel mass cytometer (Helios) with a state-of-the-art tissue imager (Hyperion). The possibility of interrogating more than 20 fluorescence-markers or more than 50 metal-markers simultaneously in millions of individual cells can unveil new cell types, functions and biomarkers for all research areas. The spatial context of tissue microenvironments across complex cellular phenotypes is empowered by the imaging capability of up to 37 protein, RNA and/or DNA markers simultaneously with 1 µm resolution. You can bring archival FFPE tissue and correlate the mass cytometry imaging with all the other data collected for those patients.


More news from the archive